Association of GLP1 ‐receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16657 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Suleiman Al Ashi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology, Diabetes, and Metabolism Fellowship, University of Central Florida HCA Healthcare GME, Greater Orlando, Florida, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Non-alcoholic Fatty Liver Disease, Hypoglycemic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 59 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease in the United States. MASLD can progress to liver cirrhosis and is associated with an increased risk of major acute cardiovascular events (MACE). This study aimed to examine the association of glucagon‐like peptide‐1 receptor agonists (GLP1‐RA) use with liver disease progression, MACE, and death from any cause among people with hepatic steatosis. Materials and Methods This retrospective cohort study using national data from the Department of Veteran Affairs included people with non‐alcoholic hepatic steatosis who initiated either GLP1‐RA or dipeptidyl‐peptidase‐4 inhibitor (DPP4i) between 1 October 2005 and 30 September 2021. Primary outcomes were: (1) liver disease progression and (2) MACE and death from any cause (MACE/death). GLP1‐RA users and DPP4i users were propensity score matched on 73 baseline characteristics.
Results
We matched 58 157 pairs of GLP1‐RA and DPP4i users. GLP1‐RA users had less liver disease progression (6.1%) compared with DPP4i users (7.0%), odds ratio (OR): 0.86; 95% confidence interval (95% CI): 0.82–0.90 and a lower risk of MACE/death (11.1% vs. 14.7%, respectively), OR: 0.72; 95% CI: 0.70–0.75. The number needed to treat to prevent one additional liver disease progression and MACE/death was 109 and 27 people, respectively.
Conclusions
Among people with diabetes and hepatic steatosis, GLP1‐RA use was associated with a lower risk of liver disease progression and a lower risk of MACE/death compared to DPP4i use. In people with MASLD, a holistic approach that seeks to lower MACE/death, beyond lowering liver disease progression alone, should be prioritised.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology, Diabetes, and Metabolism Fellowship, University of Central Florida HCA Healthcare GME, Greater Orlando, Florida, USA.
- Section of Endocrinology, Orlando VA Medical Center, Orlando, Florida, USA.
- Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, Florida, USA.
- Section of Gastroenterology and Hepatology, Orlando VA Healthcare System, Orlando, Florida, USA.
- Gastroenterology Fellowship, University of Central Florida/HCA Florida Healthcare, Florida, USA.
- College of Liberal Arts and Sciences, University of Florida, Gainesville, Florida, USA.
ORCID-Profile: Ildiko Lingvay, Ishak A Mansi
Zitieren
APA
Al Ashi, S., Shah, R., Iftikhar, N., Lingvay, I., Kinaan, M., & Mansi, I. A. (2025). Association of GLP1 ‐receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16657
Vancouver
Al Ashi S, Shah R, Iftikhar N, Lingvay I, Kinaan M, Mansi IA. Association of GLP1 ‐receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16657
BibTeX
@article{AlAshi2025,
author = {Al Ashi, Suleiman and Shah, Raj and Iftikhar, Nofel and Lingvay, Ildiko and Kinaan, Mustafa and Mansi, Ishak A},
title = {Association of GLP1 ‐receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16657}
}
EUVIMED